NF-κB as a Therapeutic Target in Inflammatory-Associated Bone Diseases.

Area of Science:

• Skeletal Biology
• Immunology
• Pharmacology

Background:

• Inflammation is crucial for skeletal homeostasis, but chronic inflammation disrupts bone formation and resorption.
• Nuclear factor kappa B (NF-κB) regulates inflammatory responses and bone remodeling, making it a key target for bone disorders.
• Conditions like fractures, nonunions, osteolysis, and osteoporosis are linked to inflammation and NF-κB activity.

Purpose of the Study:

• To explore the therapeutic potential of targeting NF-κB pathways in inflammation-associated bone disorders.
• To address the challenges and recent advancements in NF-κB-targeting therapies for skeletal conditions.
• To highlight the role of temporal modulation and advanced drug delivery in NF-κB-based bone treatments.

Main Methods:

• Review of in vitro and in vivo evidence on NF-κB's role in bone remodeling and inflammation.
• Analysis of canonical and noncanonical NF-κB pathways in skeletal cells.
• Evaluation of novel NF-κB inhibitors and drug delivery strategies.

Main Results:

• NF-κB is a critical regulator of both inflammation and bone remodeling, suggesting dual therapeutic benefits.
• Challenges include pathway complexity, essential roles in early bone healing, and potential off-target effects.
• Novel inhibitors and targeted/controlled drug delivery systems show promise for clinical translation.

Conclusions:

• Temporal modulation of NF-κB pathways combined with advanced bone-targeting drug delivery is a highly translational strategy.
• This approach can effectively reestablish skeletal homeostasis in various bone disorders.
• NF-κB inhibition presents a viable therapeutic avenue for managing inflammation-related bone pathologies.